The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SECOMBIT (sequential combo immuno and target therapy study): A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with metastatic melanoma and BRAF mutation.
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda
Research Funding - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda
 
Ignacio Melero
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Genentech; Lilly; Roche
Research Funding - Bristol-Myers Squibb; Pfizer; Roche
Travel, Accommodations, Expenses - Genentech; Roche
 
Giuseppe Palmieri
Consulting or Advisory Role - Novartis; Pierre Fabre
 
Diana Giannarelli
No Relationships to Disclose
 
Elena Abrami
No Relationships to Disclose
 
Marcello Curvietto
No Relationships to Disclose
 
Ester Simeone
No Relationships to Disclose
 
Antonio Maria Grimaldi
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono